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Abstract
To examine patterns of mono- versus polydrug abuse, data were obtained from intake records of
69,891 admissions to publicly funded treatment programs in Tennessee between 1998 and 2004.
While descriptive statistics were employed to report frequency and patterns of mono- and
polydrug abuse by demographic variables and by study years, bivariate logistic regression was
applied to assess the probability of being a mono- or polydrug abuser for a number of demographic
variables. The researchers found that during the study period 51.3% of admissions reported
monodrug abuse and 48.7% reported polydrug abuse. Alcohol, cocaine, and marijuana were the
most commonly abused substances, both alone and in combination. Odds ratio favored polydrug
abuse for all but one drug category–other drugs. Gender did not affect drug abuse patterns;
however, admissions for African Americans and those living in urban areas exhibited higher
probabilities of polydrug abuse. Age group also appeared to affect drug abuse patterns, with higher
odds of monodrug abuse among minors and adults over 45 years old. The discernable prevalence
of polydrug abuse suggests a need for developing effective prevention strategies and treatment
plans specific to polydrug abuse.
Background
Alcohol and illicit drug abuse continues to be a major
public health concern in the United States. According to
the U.S. Department of Health and Human Services'
(DHHS) 2005 National Survey on Drug Use and Health,
6.6% (16 million) of Americans age 12 or older reported
heavy drinking, 22.7% (55 million) reported binge drink-
ing, and 8.1% (19.7 million) reported using illicit drugs
within the month prior to the survey [1]. A DHHS survey
in 2002 found that 56% of all admissions to publicly
funded treatment facilities were for multiple substances;
among these admissions, 76% abused alcohol, 55%
abused marijuana, 48% abused cocaine, 27% abused opi-
ates, and 26% abused other drugs [2]. Despite the high
rates of polydrug abuse, the literature on this issue is lim-
ited. In addition, there are few studies reporting the prob-
ability of mono- versus polydrug abuse across various
demographic characteristics. Drawing upon 7 years
(1998–2004) of admission data, this study examines the
patterns of mono- versus polydrug abuse among admis-
sions to publicly funded alcohol and drug abuse treat-
ment programs in Tennessee.
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The World Health Organization defines polydrug abuse as
the concurrent (taken at the same time) or sequential (one
drug taken followed by another) abuse of more than one
drug or type of drug, with dependence upon at least one
[3]. Such abuse has been increasingly reported in emer-
gency room admissions and has been linked to drug-
related deaths as well as nonfatal overdoses [4-7]. The
abuse of multiple substances has a long recorded history
in the United States, dating to the early 20th century when
combination drug abuse was found among 11.9% of nar-
cotic addicts in New York and 1% of patients in Louisiana
[8]. During the 1960s, polydrug abuse increased drasti-
cally; for example, barbiturate abuse was noted among
29% of heroin addicts and 32.4% of narcotic addicts in
Lexington, Kentucky, as well as among the urban heroin
addicts who would alternate alcohol with illicit drug
abuse, at times as a detoxification method [8].
Alcohol abusers often report abuse of other substances. In
a study of 248 alcoholics seeking substance abuse treat-
ment, 68% reported using additional drugs in the 90 days
prior to admission [9]. Another recent study found that
over 80% of the alcoholics in treatment were dependent
on at least one other substance, most often marijuana or
cocaine. Conversely, alcohol abuse was noted among
admissions who were primarily in treatment for depend-
ence on illicit drugs–84% for cocaine, 71% for barbitu-
rates, 67% for opiates, and 64% for hallucinogens [10].
Other studies have revealed a prevalence for polydrug
abuse as well. Darke and Hall found that monodrug abuse
was rare among 329 heroin abusers and 301 ampheta-
mine abusers during a 6-month study period [11]. Leri et
al. surveyed 1,111 injection drug abusers regarding their
combination of cocaine and heroin abuse and found that
approximately 15% not being treated in methadone
maintenance programs were co-abusers of the drugs. This
study also found that the individuals who abused both
drugs tended to abuse them sequentially as opposed to
simultaneously [12]. Additionally, researchers have noted
that polydrug abusers who combine cocaine and heroin
do so to achieve specific effects not attainable with just
one substance; this practice can transform primary abuse
of one drug into a pattern of polydrug abuse [13].
While there has been some research examining predictive
variables associated with polydrug abuse, these studies
have focused on psychological aspects of the abusers,
including high scores on various psychometric scales [14]
or a range of psychosocial factors such as depression, psy-
chological distress, family support/bonding, and social
conformity as a proxy for traditional values [15]. The
study presented here statistically examines demographic
characteristics and drug abuse patterns of a large statewide
dataset of publicly funded admissions to substance abuse
treatment programs over a 7-year period (1998–2004) in
Tennessee. The goals of this paper include: 1) determining
patterns of mono- or polydrug abuse; 2) identifying the
most prevalent combinations of polydrug abuse; and 3)
examining the probability of mono- versus polydrug
abuse by demographic variables.
Methods
Data collection
Data used in this study were collected by the Division of
Alcohol and Drug Abuse Services (hereafter, the Division)
of the Tennessee Department of Mental Health and Devel-
opmental Disabilities from treatment agencies that are
funded by DHHS' Substance Abuse Prevention and Treat-
ment (SAPT) Block Grant, which provides over 75% of the
publicly funded alcohol and drug abuse services in the
state [16]. All treatment facilities receiving SAPT funds are
required to collect data for each admission on the client
being treated, including his or her demographics, sub-
stance abuse history and current patterns of abuse, and the
criminal justice system involvement.
Because the data is collected for each admission, there can
be multiple admissions representing the same client. A cli-
ent who is admitted first to an inpatient residential facility
and then is transferred to a halfway house will have two
admissions in the same dataset. Thus, the number of treat-
ment episodes is most likely overestimated. However, this
approach is the same as that used by the federal Substance
Abuse and Mental Health Services Administration
(SAMHSA), which reports the Treatment Episode Data
Sets (TEDS) based on all admissions (SAMHSA TEDS
1995–2005) for the SAPT Block Grant clients. Similarly,
the dataset for this study is limited to those clients who
obtained publicly funded treatment. There was no mech-
anism in place for obtaining information about clients
receiving treatment not funded by public funds. In addi-
tion, because the state of Tennessee neither collects data
on nicotine use nor provides smoking cessation interven-
tions through the Division, this study does not include
nicotine in the examination of polydrug abuse as reported
by a few other researchers [15,17-20].
Data in Tennessee are compiled into a statewide database
using Insight-CH software, which has specific modules for
demographic variables, such as gender, age, ethnicity,
employment, occupation, marital status, household
income, and living arrangement, as well as referrals to
treatment, substance abuse history and patterns, fre-
quency of abuse, routes of administration, arrest record
and legal status, medical history and conditions, and the
recommended American Society of Addiction Medicine
(ASAM) level of treatment. This data is made available to
the Institute for Substance Abuse Treatment Evaluation (I-
SATE) at The University of Memphis for use primarily asSubstance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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baseline data for conducting an annual outcomes evalua-
tion, but it is also available for further analysis and
research. The University of Memphis's use of the data for
both evaluation and research purposes is approved and
monitored by the University's Institutional Review Board
(IRB).
Data analysis
Microsoft Access and Visual Basic were employed to pre-
pare intake data, and SAS/Base and SAS/STAT were used
for statistical analyses. Data were first analyzed to provide
information regarding the study sample, including demo-
graphic characteristics and types of substances reported at
admission. Substances were categorized as alcohol (beer,
wine, liquor), cocaine (crack, coke, dust), marijuana
(hashish, pot, dope), opiates (heroin, methadone, Oxy-
Contin), sedatives (methaqualone, phenobarbital, Dori-
den), stimulants (amphetamine, methamphetamine,
methylphenidate [Ritalin], MDMA [Ecstasy]), hallucino-
gens (LSD, peyote, mushrooms), inhalants (aerosols, sol-
vents, nitrites, anesthetics, and others), and other drugs
(mostly club drugs such as GHB/GBL, Ketamine, diphen-
hydramine, diphenylhydantoin/phenytoin, Dilantin).
Descriptive statistics were used to report the frequency
and patterns of mono- versus polydrug abuse across
demographic variables and study years. Further analyses
were conducted to assess the probability of mono- versus
polydrug abuse for each substance category and to find
the most frequent combinations of substances among
polydrug abusers. In addition, bivariate logistic regression
was applied to determine the odds of mono- versus poly-
drug abuse for each of the demographic variables and
study years examined.
Results
Study participants
Over the 7-year period, there were 70,427 admissions to
183 agencies in Tennessee for treatment funded by the
SAPT Block Grant. Those with missing drug abuse infor-
mation (n = 536) were removed from the analysis, leaving
a total of 69,891 admissions in the study sample. Of the
admissions included, 68.9% were male and 90.0% were
adults (18 years or older), with most (n = 42,564; 60.9%)
falling between the ages of 25 and 44 (see Table 1). The
majority were Caucasian (n = 46,910; 69.2%), one third
were African American (n = 20,393; 30.1%), and only a
few were of Hispanic or other ethnic origins (n = 495;
0.7%). The study sample was almost evenly divided
between those living in urban (n = 35,062; 50.2%) and
rural (n = 34,829; 49.8%) areas. Over the study period
(1998–2004), the annual number of admissions to treat-
ment programs in this study ranged from a low of 9,123
(13.1%) in 1999 to a high of 10,738 (15.4%) in 2003.
Patterns of mono- vs. polydrug abuse
Table 2 presents the drugs abused by the study sample,
breaks the totals for each category into mono- or polydrug
abuse, and reports the likelihood of mono- versus poly-
drug abuse for each substance. Alcohol was the most fre-
quently reported substance (n = 45,318; 64.8%), followed
by cocaine (n  = 28,230; 40.4%) and marijuana (n  =
24,671; 35.3%). Opiate abuse was reported by 12.4% (n
= 8,652) of all admissions, sedatives by 6.7%, and other
drugs by 6.0%. The least reported categories were amphet-
amines (n = 3,711; 5.3%), hallucinogens (n = 711; 1.0%),
and inhalants (n  = 467; 0.7%). Overall, slightly more
admissions reported monodrug abuse (n  = 35,875;
51.3%) than polydrug abuse (n = 34,016; 48.7%). Within
each drug category, admissions were separated into
mono- versus polydrug abusers. Of all admissions who
reported alcohol abuse, 39.9% (n  = 18,078) reported
solely abusing alcohol compared to 60.1% (n = 27,240)
who reported abusing alcohol along with some other sub-
stance. Similarly, 77.8% (n = 21,970) of the admissions
reporting cocaine abuse and 79.9% (n = 19,710) of those
using marijuana were polydrug abusers. Higher propor-
tions of polydrug abuse were seen among the lesser
abused drugs; over 90% of sedative and hallucinogen
Table 1: Demographics of Study Sample (N = 69,891)
Frequency
Variable n %
Gender
Male 48,168 68.9
Female 21,723 31.1
Ethnicitya
Caucasian 46,910 69.2
African American 20,393 30.1
Other 495 0.7
Ageb
<18 6,955 10.0
18–24 10,701 15.3
25–34 20,671 29.6
35–44 21,893 31.3
45–54 8,266 11.8
≥ 55 1,404 2.0
Residential Area
Urban 35,062 50.2
Rural 34,829 49.8
Year Admitted to Treatment
1998 9,911 14.2
1999 9,123 13.1
2000 9,598 13.7
2001 10,214 14.6
2002 9,891 14.2
2003 10,738 15.4
2004 10,416 14.9
a2,093 missing ethnicity responses were removed from the total N for 
ethnicity percentages.
b1 missing age response.Substance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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abusers and about 80% of amphetamine and inhalant
abusers reported polydrug abuse. The category of "other
drugs," mostly comprising club drugs, constituted the
only category that had more mono- (n = 2,836; 68.0%)
than polydrug (n = 1,336; 32.0%) abuse.
Using bivariate logistic regression, an odds ratio for each
drug was calculated to estimate the likelihood of mono-
versus polydrug abuse. "Other drugs" showed more than
twice the likelihood that a client would be a monodrug
abuser (OR = 2.122, CI = 1.989–2.199). Individuals in the
rest of the drug categories were significantly more likely to
be polydrug abusers (ORs < 1.00, p-values < 0.0001).
Despite only a marginal difference among all abusers (less
than 3%) in the frequency of those reporting mono- ver-
sus polydrug abuse, analyses of individual drug categories
explicitly showed a higher probability of polydrug abuse
in all but one category.
Prevalent combinations of substance abuse
Most polydrug abusers reported combining two or three
substances (see Table 3). Over the 7-year period, roughly
30% (n = 20,789) of the entire client base reported using
two substances, less than a fifth (n  = 10,711; 15.3%)
reported using three substances, and approximately 4%
abused four or more drugs. While those who abused two
types of substances reported 35 of the 36 possible combi-
nations of two drugs, only 67 of the 84 possible combina-
tions of three substances were reported, and even fewer of
the possibilities combining four or more substances were
reported by abusers. Substances abused in the most prev-
alent dyads or triads are presented in Table 4. The most
common two-substance combination recorded was alco-
hol/cocaine at 12.0% (n = 8,374) of all admissions, fol-
lowed by alcohol/marijuana (n = 5,182; 7.4%), cocaine/
marijuana (n = 2,371; 3.4%), and alcohol/opiates (n =
916; 1.3%). Among three-substance abusers, the triad of
Table 3: Combinations of Substances Used (N = 69,891)
Number of 
Substances Used
Possible Number of 
Drug Combinations
Number of Drug 
Combinations Found
Number of Admissions
n %
1 N/A N/A 35,875 51.3
2 36 35 20,789 29.8
3 84 67 10,711 15.3
4 126 68 1,833 2.6
5 126 46 478 0.7
68 4 2 91 4 0 0 . 2
73 6 1 3 4 7 0 . 0 6 7
89 6 1 7 0 . 0 2 4
91 1 1 0 . 0 0 1 4
Table 2: Mono- vs. Polydrug Abuse Reported (N = 69,891)
Total Usersa Monodrug Users Polydrug Users
N = 69,891 35,875 51.3% 34,016 48.7% Odds Ratio
Substance n % n % n %O R b 95% CI
Alcohol 45,318 64.8 18,078 39.9 27,240 60.1 0.664 0.651–0.670
Cocaine 28,230 40.4 6,260 22.2 21,970 77.8 0.285 0.277–0.289
Marijuana 24,671 35.3 4,961 20.1 19,710 79.9 0.252 0.244–0.256
Opiates 8,652 12.4 2,492 28.8 6,160 71.2 0.405 0.386–0.415
Sedatives 4,690 6.7 363 7.7 4,327 92.3 0.084 0.075–0.089
Amphetamines 3,711 5.3 752 20.3 2,959 79.7 0.254 0.235–0.265
Hallucinogens 711 1.0 42 5.9 669 94.1 0.063 0.046–0.074
Inhalants 467 0.7 91 19.5 376 80.5 0.242 0.192–0.273
Other drugsc 4,172 6.0 2,836 68.0 1,336 32.0 2.122 1.989–2.199
Note: Percentages for mono and polydrug abuse are calculated from Total Users of each substance across rows and not down columns; n values are 
actual number of users.
a This column reflects mono- and polydrug use for each particular substance category. Frequencies (N, %) do not add up to total users or 100% 
because of multiple responses among categories.
b For each drug, odds ratio indicates the likelihood of the client's being a mono- or polydrug user when reporting that substance as the one requiring 
treatment. Odds ratios were estimated from bivariate logistic regression analysis; all were significant at p < 0.0001.
c Other drugs refers mostly to club drugs, such as ecstasy, GHB, Ketamine, and Rohypnol.Substance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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alcohol/cocaine/marijuana was the most reported,
abused by nearly 9% of the study sample (n = 6,202), dis-
tantly followed by alcohol/cocaine/opiates (n  = 663;
1.0%). Each of the remaining two- and three-substance
combinations accounted for less than 1% of all admis-
sions.
Mono- versus polydrug abuse by demographic variables
Mono- and polydrug abuse examined by demographic
variables using bivariate logistic regression yielded several
notable results (see Table 5). For both male and female
admissions, there was no difference in the likelihood of
being a mono- or polydrug abuser (OR = 0.979, p = 0.130
and OR = 1.021, p < 0.10). Caucasian admissions were
found to be twice as likely to be monodrug abusers (OR =
1.957, p < 0.0001) compared to other ethnicities, while
African Americans were twice as likely to be polydrug
abusers (OR = 0.504, p < 0.0001). Admissions of all other
ethnicities, primarily Hispanics, were equally as likely to
be mono- as polydrug abusers (OR = 1.154, p = 0.113).
Adolescents (those under 18 years of age) were almost
twice as likely to be monodrug abusers (OR = 1.876, p <
0.0001). Adults from 18 to 44 years old were slightly more
likely to be polydrug abusers (ORs < 0.90, p-values <
0.0001), while adults 45 and over were significantly more
likely to be monodrug abusers, especially those 55 and
older (OR = 1.466 for ages 45–54 and OR = 3.950 for ages
≥ 55). Admissions in urban settings were more likely to be
polydrug abusers (OR = 0.802, p < 0.0001), whereas rural
admissions were more likely to be monodrug abusers (OR
= 1.248, p < 0.0001). Across the 7 study years, there was a
small overall decline in polydrug abuse from 53.1% of
admissions in 1998 to 48.2% in 2004, but the decline was
not consistent, falling to a low of 44.9% in 2000, then ris-
ing to 50.6% in 2002 before resuming a general decline.
There is no clear pattern across the 7 study years in terms
of likelihood of mono- versus polydrug abuse. Other than
in 1998 and 1999, when the likelihood of polydrug abuse
was slightly higher, there was no difference in the likeli-
hood of admissions for mono- or polydrug abuse from
year to year.
Discussion
This study revealed that for both mono- and polydrug
abusers, alcohol was the predominant substance of
choice, followed by cocaine and marijuana, findings con-
sistent with those reported by other national surveys
[2,17,20]. These three substances were also the most com-
mon in two- and three-substance combinations reported
by this study sample–at least one of these substances was
part of 13 of the top 14 substance pairings and at least two
were found in 11 of the top 15 triads. This strongly con-
curs with earlier studies in which the most frequent poly-
drug combinations included alcohol, specifically
marijuana with alcohol, followed by alcohol with other
illicit drugs, and marijuana with other illicit drugs
[2,9,10,17]. Whereas some other researchers used the gen-
eral category of "illicit drugs," this study explicitly identi-
fied cocaine as the illicit substance. In terms of total
overall abuse, cocaine abuse was second only to alcohol
and was reported in the most frequently abused two- and
three-substance combinations.
Despite these similarities, in many ways the results of this
research are quite different from those reported in previ-
ous studies. We found slightly lower polydrug abuse rates
than the national trends reported by the Treatment Epi-
sode Data Set (TEDS) [21]. In a report of longitudinal
trends of substance abuse from 1994–2005, only 44.2%
of all admissions in 2005 reported no substance abuse in
addition to the primary substance (p.163). The TEDS data
Table 4: Most Common Substance Combinations (N = 69,891)
Substance Combination n %a
Two substances (n = 20,789; 29.8%)
Alcohol, Cocaine 8,374 12.0
Alcohol, Marijuana 5,182 7.4
Cocaine, Marijuana 2,371 3.4
Alcohol, Opiates 916 1.3
Cocaine, Opiates 593 0.9
Amphetamines, Marijuana 449 0.6
Opiates, Sedatives 445 0.6
Alcohol, Sedatives 429 0.6
Marijuana, Opiates 395 0.6
Alcohol, Otherb 282 0.4
Alcohol, Amphetamines 260 0.4
Marijuana, Sedatives 187 0.3
Cocaine, Amphetamines 159 0.2
Marijuana, Otherb 104 0.2
Combinations with n < 100 643 0.9
Three substances (n = 10,711; 15.3%)
Alcohol, Cocaine, Marijuana 6,202 8.9
Alcohol, Cocaine, Opiates 663 1.0
Alcohol, Marijuana, Sedatives 483 0.7
Alcohol, Sedatives, Otherb 430 0.6
Alcohol, Marijuana, Amphetamines 388 0.6
Alcohol, Opiates, Sedatives 327 0.5
Alcohol, Cocaine, Sedatives 275 0.4
Cocaine, Marijuana, Opiates 241 0.3
Alcohol, Cocaine, Amphetamines 167 0.2
Marijuana, Opiates, Sedatives 153 0.2
Cocaine, Marijuana, Amphetamines 151 0.2
Cocaine, Marijuana, Sedatives 129 0.2
Alcohol, Marijuana, Otherb 125 0.2
Alcohol, Cocaine, Otherb 118 0.17
Cocaine, Opiates, Sedatives 118 0.17
Combinations with n < 100 741 1.1
aPercentages are based on the entire client base and not just those 
abusing two or three substances.
bOther refers mostly to club drugs, such as ecstasy, GHB, Ketamine, 
and Rohypnol.Substance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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also indicated that roughly half of adolescents between
the ages of 12 and 17 who were admitted for substance
abuse treatment were being treated for a combination of
both alcohol and marijuana, although that proportion
has been steadily decreasing since 1999 to about 43% of
admissions in 2005 (p.156). While the majority (55.1%)
of admissions for treatment of alcohol did not report
abuse of other substances, admissions with other sub-
stances as the primary substance of abuse reported
roughly 24.7 to 41.7% being treated for a single substance
(p.163). So far, TEDS has not reported polydrug data by
state, preventing a direct comparison with the results of
this research in Tennessee.
Examinations of demographic characteristics of polydrug
abusers, such as age, gender, and ethnicity, in order to
identify trends have found that, in general, polydrug
abuse was lowest for those over 40 years old and highest
among those under 20 [2,22-24]. For example, Chen and
Kandel found a tendency for polydrug abusers to be
young, with initiation of illicit polydrug abuse being
extremely rare after age 20 [22]. The DHHS found that
65% of admissions under 20 reported polydrug abuse,
whereas only 41% of admissions over 45 did so [2]. Exam-
ining polydrug abuse by age group among national
admissions to publicly funded substance abuse treatment,
Henderson found peak polydrug abuse among those
younger than 40 [23]. Earleywine and Newcomb found
that a majority of polydrug abuse took place among those
age 28–32, who constituted 31% of the combination
abusers of marijuana and alcohol, 28% of alcohol and
illicit drugs other than marijuana, and 22% of marijuana
with other illicit drugs [25]. Collins et al. found polydrug
abuse in 29% of 12th graders studied [26]. The American
Academy of Family Physicians reported the abuse of mul-
tiple drugs by more than two thirds of patients age 20–30
and among more than four fifths of those under 20 [27].
Several other studies found high levels of polydrug abuse
among adolescents [17,23,28]. At the same time, research
has suggested that the incidence of polydrug abuse may
decline with age. For example, Raveis and Kandel deter-
mined that 85–95% of abusers, other than those who
Table 5: Likelihood of Mono- versus Polydrug Abuse by Demographic Variables and Study Years (N = 69,891)
Total Users Monodrug Users Polydrug Users
N = 69,891 n = 35,875 (51.3%) n = 34,016 (48.7%) Odds Ratio
Variable N % n % n %O R a 95% CI
Gender
Male 48,168 68.9 24,646 51.2 23,522 48.8 0.979c 0.948–1.011
Female 21,723 31.1 11,229 51.7 10,494 48.3 1.021c 0.989–1.055
Ethnicity
Caucasian 46,910 69.2 26,218 55.9 20,692 44.1 1.957b 1.893–2.023
African American 20,393 30.1 7,941 38.9 12,452 61.1 0.504b 0.487–0.521
Other 495 0.7 269 54.3 226 45.7 1.154ns 0.967–1.379
Age
<18 6,955 10.0 4,525 65.1 2,430 34.9 1.876b 1.782–1.976
18–24 10,701 15.3 5,111 47.8 5,590 52.2 0.845b 0.811–0.880
25–34 20,671 29.6 9,347 45.2 11,324 54.8 0.706b 0.683–0.730
35–44 21,893 31.3 10,833 49.5 11,060 50.5 0.898b 0.870–0.927
45–54 8,266 11.8 4,931 59.7 3,335 40.3 1.466b 1.399–1.536
≥ 55 1,404 2.0 1,127 80.3 277 19.7 3.950b 3.461–4.509
Residential Area
Urban 35,062 50.2 17,035 48.6 18,027 51.4 0.802b 0.779–0.826
Rural 34,829 49.8 18,840 54.1 15,989 45.9 1.248b 1.210–1.285
Year
1998 9,911 14.2 4,645 46.9 5,266 53.1 0.812b 0.778–0.847
1999 9,123 13.1 4,327 47.4 4,796 52.6 0.836b 0.800–0.873
2000 9,598 13.7 5,293 55.1 4,305 44.9 1.194b 1.144–1.247
2001 10,214 14.6 5,618 55.0 4,596 45.0 1.189b 1.139–1.240
2002 9,891 14.2 4,885 49.4 5,006 50.6 0.913b 0.875–0.953
2003 10,738 15.4 5,711 53.2 5,027 46.8 1.092b 1.048–1.138
2004 10,416 14.9 5,396 51.8 5,020 48.2 1.023ns 0.981–1.066
aOdds ratio of being a mono- versus a polydrug user in comparing a specific level of client demographics to all other demographic features. Odds in 
this table are calculated for the odds of being a mono vs. polydrug abuser, not for being male rather than female.
bp < 0.0001.
cp < 0.10.
nsNot significant.Substance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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were marijuana and alcohol dependent, had ceased mul-
tiple drug abuse by age 28–29 [24], and Darke and Hall
noted that among heroin and amphetamine abusers the
number of drugs used tended to decrease with age [11]. In
contrast to these previous studies, this research found that
while polydrug abuse was higher among clients between
the ages of 18 and 44, monodrug abuse prevailed among
minors and adults over 55.
Earlier research also found that males exhibited more
polydrug abuse than females [11,17,18]. In this study,
however, males and females were equally likely to be
polydrug abusers. With regard to ethnicity, our research
differed from previous studies as well. Asians have been
shown to be less likely than African Americans, Hispanics,
or Caucasians to be polydrug abusers [15,18], and African
Americans have been found to be less likely to be poly-
drug abusers than Hispanics or Caucasians [18]. Our find-
ings indicated that Caucasians were more likely to be
monodrug abusers and African Americans were more
likely to be polydrug abusers, in direct contrast to prior
reports of lower rates of polydrug abuse among African
Americans than Caucasians [18]. Additionally, although
there is little in the substance abuse literature regarding
rural versus urban polydrug abuse in the United States,
this study found that admissions in urban areas were
more likely to be for polydrug abuse, while rural admis-
sions were more likely to be for monodrug abuse.
The variation in study results discussed above suggests
that accounting for regional differences in substance
abuse patterns may be very important, if not determinant,
in the implementation of public health policy at the state
level. National estimates, even the state breakdowns pro-
vided in SAMHSA's National Survey on Drug Use and
Health, may be less reliable than comprehensive, multi-
year research derived from local treatment providers, such
as the findings presented here.
Conclusion
Although this study is based on a large dataset, it is limited
in that the study sample consisted only of admissions to
publicly funded treatment in Tennessee. In other areas of
the country, there may be different patterns of mono- and
polydrug abuse among those admitted to private treat-
ment facilities, or among substance abusers in the general
population not seeking treatment. The national data
available from SAMHSA also comprised publicly funded
admissions; this means that there is no other major data-
set with which to compare publicly funded admissions
with other types to discern differences, if applicable,
between publicly funded and nonpublicly funded admis-
sions. Finally, this research did not address several other
variables that have been independently associated with
polydrug abuse, including not being in treatment, using
drugs intravenously, sharing injection paraphernalia,
being an amphetamine abuser, and being partially or fully
disabled and/or having co-occurring mental health prob-
lems [10,11,29]. Despite these limitations, this study
highlights the prevalence of polydrug abuse, a phenome-
non that is as common as monodrug abuse, and examines
the probability of mono- versus polydrug abuse by demo-
graphic variables.
Most of what is known about substance abuse in the
United States does not distinguish between mono- and
polydrug abuse, a gap in the research that has potentially
adverse implications for substance abuse prevention and
treatment policies. The complex nature of mono- versus
polydrug abuse and the frequency with which cases of pri-
mary abuse of one substance easily led to a pattern of
polydrug abuse [13] indicates that substance abuse treat-
ment professionals must have a full range of protocols
available to help them provide optimal intervention serv-
ices. Drug treatment interventions tailored to the specific
characteristics of the population are generally more suc-
cessful [30,31]. Protocols have already been developed
specifically for adolescents [32,33], minorities [34], cli-
ents with co-occurring mental illness [35,36], and clients
with HIV [34], to name a few. The present study provides
valuable data about the prevalence and patterns of mono-
versus polydrug abuse in a statewide treatment popula-
tion, which can be used to assist in developing the most
effective prevention and treatment plans for these popula-
tions.
Polydrug abuse has a significant public health impact. The
interaction among multiple drugs can heighten the neuro-
logical, physiological, and psychological impact on the
user as well as potentially increase the negative conse-
quences of polydrug abuse. In addition, as Schensul et al.
[37] notes " [c]umulative multiple drug use is associated
with poorer physical health, greater likelihood of addic-
tion, and other social and mental health problems"
(p.571). For example, after examining data from the Drug
Abuse Warning Network (DAWN), McCabe et al. deter-
mined that most emergency room visits related to drug
intake involved polydrug abuse, especially the combina-
tion of prescription medication with alcohol [38]. The
consequences may be even more serious; Cone et al.
found that the overwhelming majority of oxycodone-
related deaths between August 1999 and January 2002
involved another drug agent [39].
Areas for future investigation might address those specific
aspects of polydrug abuse that might impact prevention
and treatment. For example, what is the array of forces/
stimuli motivating polydrug abuse, and how do these vary
according to demographics? Is polydrug abuse chronic or
simply one stage in the life of a substance abuser? If weSubstance Abuse Treatment, Prevention, and Policy 2007, 2:33 http://www.substanceabusepolicy.com/content/2/1/33
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followed a polydrug abuser across time, would we find
periods when he or she was a monodrug abuser, and other
times a polydrug abuser? The answers to these questions
have important policy implications, especially in terms of
providing polydrug abusers with the most effective treat-
ment regimen.
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